Hodgkin lymphoma in older patients: An uncommon disease in need of study

Andrew M. Evens, John W. Sweetenham, Sandra J. Horning

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Elderly Hodgkin lymphoma (HL), commonly defined as occuring in patients over 60 to 65 years of age, is an uncommon disease. In population-based studies, the proportion of HL patients over age 60 years has ranged from 15% to 30%. However, the proportion of patients over age 60 years in clinical trials has been considerably lower, typically constituting < 5% to 10% of participants. Elderly HL patients commonly present with mixed cellularity histology, B symptoms, advanced stage, and Epstein-Barr virus-positive disease. Progression-free and overall survival rates for elderly HL patients are disproportionately inferior to those of younger patients. Generally, treatment of elderly HL for all disease stages should be given with curative intent, but more effective, tolerable therapeutic regimens are needed. No standard treatment recommendations exist for elderly HL. Bleomycin-containing regimens including ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine) are associated with pulmonary toxicity, and intensive therapy such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine [Oncovin], procarbazine [Matulane], prednisone) is poorly tolerated, whereas less-intensive regimens such as CVP/CEB (chlorambucil [Leukeran], vinblastine, procarbazine, prednisone, cyclophosphamide, etoposide, bleomycin) and ChlVPP (chlorambucil, vinblastine, procarbazine, prednisolone) appear to be less effective than anthracycline-based regimens. Recent data using CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in this population merit further investigation. In addition, further evaluation of the prognostic value of early PET in elderly HL is warranted. Continued multicenter collaborations with prospective clinical trials, including formal assessment of comorbidity and functional status, will be critical to the successful study of elderly HL.

Original languageEnglish (US)
Pages (from-to)1369-1379
Number of pages11
JournalONCOLOGY
Volume22
Issue number12
StatePublished - Nov 15 2008
Externally publishedYes

Fingerprint

Hodgkin Disease
Procarbazine
Bleomycin
Chlorambucil
Doxorubicin
Vinblastine
Vincristine
Prednisone
Cyclophosphamide
Etoposide
Clinical Trials
Dacarbazine
Anthracyclines
Virus Diseases
Therapeutics
Prednisolone
Human Herpesvirus 4
Population
Disease-Free Survival
Comorbidity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hodgkin lymphoma in older patients : An uncommon disease in need of study. / Evens, Andrew M.; Sweetenham, John W.; Horning, Sandra J.

In: ONCOLOGY, Vol. 22, No. 12, 15.11.2008, p. 1369-1379.

Research output: Contribution to journalArticle

Evens, AM, Sweetenham, JW & Horning, SJ 2008, 'Hodgkin lymphoma in older patients: An uncommon disease in need of study', ONCOLOGY, vol. 22, no. 12, pp. 1369-1379.
Evens, Andrew M. ; Sweetenham, John W. ; Horning, Sandra J. / Hodgkin lymphoma in older patients : An uncommon disease in need of study. In: ONCOLOGY. 2008 ; Vol. 22, No. 12. pp. 1369-1379.
@article{af1307290ff64c0bbd188018c1031e80,
title = "Hodgkin lymphoma in older patients: An uncommon disease in need of study",
abstract = "Elderly Hodgkin lymphoma (HL), commonly defined as occuring in patients over 60 to 65 years of age, is an uncommon disease. In population-based studies, the proportion of HL patients over age 60 years has ranged from 15{\%} to 30{\%}. However, the proportion of patients over age 60 years in clinical trials has been considerably lower, typically constituting < 5{\%} to 10{\%} of participants. Elderly HL patients commonly present with mixed cellularity histology, B symptoms, advanced stage, and Epstein-Barr virus-positive disease. Progression-free and overall survival rates for elderly HL patients are disproportionately inferior to those of younger patients. Generally, treatment of elderly HL for all disease stages should be given with curative intent, but more effective, tolerable therapeutic regimens are needed. No standard treatment recommendations exist for elderly HL. Bleomycin-containing regimens including ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine) are associated with pulmonary toxicity, and intensive therapy such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine [Oncovin], procarbazine [Matulane], prednisone) is poorly tolerated, whereas less-intensive regimens such as CVP/CEB (chlorambucil [Leukeran], vinblastine, procarbazine, prednisone, cyclophosphamide, etoposide, bleomycin) and ChlVPP (chlorambucil, vinblastine, procarbazine, prednisolone) appear to be less effective than anthracycline-based regimens. Recent data using CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in this population merit further investigation. In addition, further evaluation of the prognostic value of early PET in elderly HL is warranted. Continued multicenter collaborations with prospective clinical trials, including formal assessment of comorbidity and functional status, will be critical to the successful study of elderly HL.",
author = "Evens, {Andrew M.} and Sweetenham, {John W.} and Horning, {Sandra J.}",
year = "2008",
month = "11",
day = "15",
language = "English (US)",
volume = "22",
pages = "1369--1379",
journal = "Oncology (Williston Park, N.Y.)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "12",

}

TY - JOUR

T1 - Hodgkin lymphoma in older patients

T2 - An uncommon disease in need of study

AU - Evens, Andrew M.

AU - Sweetenham, John W.

AU - Horning, Sandra J.

PY - 2008/11/15

Y1 - 2008/11/15

N2 - Elderly Hodgkin lymphoma (HL), commonly defined as occuring in patients over 60 to 65 years of age, is an uncommon disease. In population-based studies, the proportion of HL patients over age 60 years has ranged from 15% to 30%. However, the proportion of patients over age 60 years in clinical trials has been considerably lower, typically constituting < 5% to 10% of participants. Elderly HL patients commonly present with mixed cellularity histology, B symptoms, advanced stage, and Epstein-Barr virus-positive disease. Progression-free and overall survival rates for elderly HL patients are disproportionately inferior to those of younger patients. Generally, treatment of elderly HL for all disease stages should be given with curative intent, but more effective, tolerable therapeutic regimens are needed. No standard treatment recommendations exist for elderly HL. Bleomycin-containing regimens including ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine) are associated with pulmonary toxicity, and intensive therapy such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine [Oncovin], procarbazine [Matulane], prednisone) is poorly tolerated, whereas less-intensive regimens such as CVP/CEB (chlorambucil [Leukeran], vinblastine, procarbazine, prednisone, cyclophosphamide, etoposide, bleomycin) and ChlVPP (chlorambucil, vinblastine, procarbazine, prednisolone) appear to be less effective than anthracycline-based regimens. Recent data using CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in this population merit further investigation. In addition, further evaluation of the prognostic value of early PET in elderly HL is warranted. Continued multicenter collaborations with prospective clinical trials, including formal assessment of comorbidity and functional status, will be critical to the successful study of elderly HL.

AB - Elderly Hodgkin lymphoma (HL), commonly defined as occuring in patients over 60 to 65 years of age, is an uncommon disease. In population-based studies, the proportion of HL patients over age 60 years has ranged from 15% to 30%. However, the proportion of patients over age 60 years in clinical trials has been considerably lower, typically constituting < 5% to 10% of participants. Elderly HL patients commonly present with mixed cellularity histology, B symptoms, advanced stage, and Epstein-Barr virus-positive disease. Progression-free and overall survival rates for elderly HL patients are disproportionately inferior to those of younger patients. Generally, treatment of elderly HL for all disease stages should be given with curative intent, but more effective, tolerable therapeutic regimens are needed. No standard treatment recommendations exist for elderly HL. Bleomycin-containing regimens including ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine) are associated with pulmonary toxicity, and intensive therapy such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine [Oncovin], procarbazine [Matulane], prednisone) is poorly tolerated, whereas less-intensive regimens such as CVP/CEB (chlorambucil [Leukeran], vinblastine, procarbazine, prednisone, cyclophosphamide, etoposide, bleomycin) and ChlVPP (chlorambucil, vinblastine, procarbazine, prednisolone) appear to be less effective than anthracycline-based regimens. Recent data using CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in this population merit further investigation. In addition, further evaluation of the prognostic value of early PET in elderly HL is warranted. Continued multicenter collaborations with prospective clinical trials, including formal assessment of comorbidity and functional status, will be critical to the successful study of elderly HL.

UR - http://www.scopus.com/inward/record.url?scp=57449093981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57449093981&partnerID=8YFLogxK

M3 - Article

C2 - 19086599

AN - SCOPUS:57449093981

VL - 22

SP - 1369

EP - 1379

JO - Oncology (Williston Park, N.Y.)

JF - Oncology (Williston Park, N.Y.)

SN - 0890-9091

IS - 12

ER -